Ovarian Function and Fertility Preservation in Breast Cancer: Should
Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal
Patients Receiving Chemotherapy?

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal breast cancer patients. Temporary ovarian suppression obtained pharmacologically with the administration of a gonadotropin-releasin...

Full description

Bibliographic Details
Main Authors:	Matteo Lambertini, François Richard, Bastien Nguyen, Giulia Viglietti, Cynthia Villarreal-Garza
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-02-01
Series:	Clinical Medicine Insights: Reproductive Health
Online Access:	https://doi.org/10.1177/1179558119828393

Similar Items

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis
by: Shen YW, et al.
Published: (2015-11-01)

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
by: Abdel-Razeq H
Published: (2019-05-01)

Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
by: Francesca Poggio, et al.
Published: (2019-07-01)

The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer
by: Eva Blondeaux, et al.
Published: (2021-06-01)

Ovarian reserve testing in premenopausal recipients of chemotherapy for breast cancer
by: Singh, K. J. D. L.
Published: (2008)

Should Chemotherapy Be Administered for Essential Thrombocythemia (ET) Patients with Leukemic Transformation?
by: Gee Chuan Wong FRCP, FAMS(Hematology)
Published: (2011-03-01)

Adjuvant gonadotropin releasing hormone analog in gonadotoxic chemotherapy for preservation of fertility
by: K. V. S. Hari Kumar, et al.
Published: (2013-01-01)

Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
by: Shiu-Dong Chung, et al.
Published: (2014-01-01)

Decreased Level of Neurotrophic Factor Neuritin 1 in Women with Ovarian Endometriosis after Receiving Gonadotropin-Releasing Hormone Agonist Treatment
by: Endah Rahmawati, et al.
Published: (2019-09-01)

Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells
by: Kuan-Hao Tsui, et al.
Published: (2014-03-01)

Gonadotropin releasing hormone agonists: Expanding vistas
by: Navneet Magon
Published: (2011-01-01)

Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients
by: Dong-Yun Lee, et al.
Published: (2020-06-01)

Triggering ovulation with gonadotropin-releasing hormone agonist versus human chorionic gonadotropin in polycystic ovarian syndrome. A randomized trial
by: Amr Hassaan Farag, et al.
Published: (2015-12-01)

Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis.
by: Chuan Wang, et al.
Published: (2013-01-01)

Effects of Gonadotropin Releasing Hormone Agonist (Buserelin) on Development of Ovarian Follicles of Adult Rats
by: Tahmineh Peirouvi, et al.
Published: (2016-08-01)

The Role of Nitric Oxide in Controlled Ovarian Stimulation with Gonadotropin-Releasing Hormone Agonist and Antagonist
by: Lee Tsung-Hsien, et al.
Published: (2003)

Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy for breast cancer in premenopausal patients. Pilot study results
by: I. B. Kononenko, et al.
Published: (2018-11-01)

The temporal reliability of serum estrogens, progesterone, gonadotropins, SHBG and urinary estrogen and progesterone metabolites in premenopausal women
by: Stanczyk Frank Z, et al.
Published: (2002-12-01)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
by: Fergus Keane, et al.
Published: (2016-06-01)

Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
by: Yaoyao Zhang, et al.
Published: (2013-01-01)

Should Pharmacy Technicians Administer Immunizations?
by: Dylan Atkinson, et al.
Published: (2017-09-01)

Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve
by: Ming-Huei Lin, et al.
Published: (2019-01-01)

Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin
by: Patenia Rebecca S, et al.
Published: (2006-04-01)

Comparison of Histopathologic Features of Endometrial Cancer Based on Menopausal Status and Safety of Ovarian Preservation in Premenopausal Women
by: Ozgur Kan, et al.
Published: (2017-07-01)

Should human chorionic gonadotropine treatment increase thyroid volume?
by: Ayten Oguz, et al.
Published: (2015-08-01)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
by: Feng Zhou, et al.
Published: (2016-01-01)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
by: Juan Carlos Castillo, et al.
Published: (2020-04-01)

pS6K1 as an efficacy marker of GnRH agonist with premenopausal breast cancer
by: Chan Sub Park, et al.
Published: (2019-06-01)

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol
by: Behnaz Khani Rabati, et al.
Published: (2012-01-01)

Clinical and endocrine responses to ovarian hyperstimulation in flare and and luteal gonadotropin-releasing hormone agonist (GnRHa) protocols
by: Nguyen, Tuan-Anh T
Published: (2008)

Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles
by: Muammer Doğan, et al.
Published: (2012-06-01)

Clinical and endocrine responses to ovarian hyperstimulation in flare and and luteal gonadotropin-releasing hormone agonist (GnRHa) protocols
by: Nguyen, Tuan-Anh T
Published: (2008)

Clinical and endocrine responses to ovarian hyperstimulation in flare and and luteal gonadotropin-releasing hormone agonist (GnRHa) protocols
by: Nguyen, Tuan-Anh T
Published: (2008)

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
by: Yen-Shen Lu, et al.
Published: (2021-09-01)

Foundation doctors in Anaesthesia: should they be taught to administer an anaesthetic?
by: Williamson Sean, et al.
Published: (2007-11-01)

Efficacy and safety of goserelin combined with adjuvant chemotherapy in premenopausal women with breast cancer
by: Yang Wang, et al.
Published: (2015-11-01)

Is it safe to preserve the ovary of premenopausal women with supposed early-stage endometrial cancer?
by: Fa-Kung Lee
Published: (2016-02-01)

Protective effect of gonadotropin-releasing hormone analog on the ovarian reserve in rats receiving cyclophosphamide treatment
by: Gui T, et al.
Published: (2015-03-01)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
by: Eun Jin Han, et al.
Published: (2013-09-01)

Aggressive angiomyxoma of the vulva: dramatic response to gonadotropin-releasing hormone agonist therapy
by: Azar Danesh, et al.
Published: (2007-08-01)